Immunotherapy of metastatic melanoma with interferon-α and interleukin-2: Pattern of progression in responders and patients with stable disease with or without resection of residual lesions
- 1 January 1994
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (7) , 955-958
- https://doi.org/10.1016/0959-8049(94)90122-8
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trialsCancer, 1993
- Relapse After Response to Interleukin-2-Based Immunotherapy: Patterns of Progression and Response to RetreatmentJournal of Immunotherapy, 1991
- Improved survival after resection of pulmonary metastases from malignant melanomaThe Annals of Thoracic Surgery, 1991
- Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.Journal of Clinical Oncology, 1989
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.Journal of Clinical Oncology, 1989
- Effect of surgical treatment on stage IV melanomaThe American Journal of Surgery, 1987
- High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated CancerJAMA, 1986
- Surgery as Palliative Treatment for Distant Metastases of MelanomaAnnals of Surgery, 1986
- Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells.The Journal of Immunology, 1984